Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes
Year: 2020
Type: article
Abstract: Immune checkpoint inhibitors (ICIs) that target programmed cell death protein 1 (PD-1) and its ligand (PD-L1), or cytotoxic T lymphocyte antigen-4 (CTLA-4) elicit durable antitumor responses in multiple cancer types. Yet, only a minority of patients could derive clinical benefit (1).
Source: Annals of Translational Medicine
Institutions: Tongji University, Shanghai Pulmonary Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
Awards: G2614017237, G3707519228, G6562790071
OpenAlex ID: W2993652631
